Be sure to check out our presentation on a ECG-based deep learning model to detect CAD European Society of Cardiology #ESCCongress today. I’m happy to show more data or chat about it if you are interested!

Rare cardiomyopathy-associated genetic variants are associated w/outcomes in AF pts. AF pts w/rare variants have more HF at dx, more HF-related hospital admissions & more cardiovascular death during follow-up. Genetic testing might affect prognosis. Nicholas Marston #ESCCongress

Great presentation by Shino Kany on using an AI model to detect CAD from the 12 lead ECG at #ESCCongress Akl Fahed ML4H Mass General Heart

We wrote about an AF heart team concept for individualizing OAC/LAAC pathways for pts a while ago. I was really happy to see that the new AF guidelines cite our concept (which we practise in UKE Hamburg). You can read about it here European Society of Cardiology Journals in EHJ academic.oup.com/eurheartj/arti…

Check out our work on the prevalence and prognostic implications of cardiomyopathy variant carriers in 5 large TIMI cardiovascular outcome trials. Nicholas Marston Patrick Ellinor

Excited to share our recent work on cross-biobank and pan-ancestry genetic analyses of rare variants for human disease 🧬 published last week in Nature Genetics Xin Wang Patrick Ellinor Link: nature.com/articles/s4158…

Nicely done Shino Kany discussing implications of CMP variant carriers in 63k patients from 5 TIMI Study Group trials European Society of Cardiology Broad Institute, Mass General Heart

In 32,000 AF pts from COMBINE-AF, cardiac #biomarkers sign.⤴️ #heartfailure risk prediction! hs-cTnT as important as NTproBNP pointing to a promising dual-marker strategy. Results simultaneously published in JACC Journals Paul M Haller Robert Giugliano #ESCCongress

Using exome seq in 63,700 pts from 5 TIMI CV outcome trials, we observed 866(1.3%) CMP variant carriers. These pts had ↑ rates of hospitalization for HF, incident AF & DCM variant carriers in particular of CV death over ~2.5 years of f/u. Nicholas Marston Shino Kany #ESCCongress

Can biomarkers improve HF risk assessment in AF patients? Superb analysis by Paul M Haller simultaneously published in JACC, shows hs-cTnT is as important as NTproBNP, with significant but lesser contribution from GDF-15. #COMBINE-AF

You may remember the neutral Statin in AS trials. But it alwys seemed like those pts had adv. disease and it was too litte too late. Here, we present genetic data that LDL causally leads to AS risk and might be a treatment target to prevent AS. Do we need earlier, bigger trials?

I love this figure and hope it will convince people that you can medically prevent AS Nicholas Marston David J. Cohen, MD, MSc